Jacobs Levy Equity Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Jacobs Levy Equity Management’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-23,557	Closed	-$27K	–	1122
2022 Q1	$27K	Hold	23,557	–	–	﹤0.01%	989
2021 Q4	$53K	Sell	23,557 -54,228	-70%	-$136K	﹤0.01%	956
2021 Q3	$266K	Hold	77,785	–	–	﹤0.01%	953
2021 Q2	$233K	Sell	77,785 -229,748	-75%	-$727K	﹤0.01%	966
2021 Q1	$993K	Buy	307,533 +165,179	+116%	+$551K	0.01%	740
2020 Q4	$302K	Sell	142,354 -135,196	-49%	-$223K	﹤0.01%	923
2020 Q3	$325K	Hold	277,550	–	–	﹤0.01%	877
2020 Q2	$251K	Buy	277,550 +13,001	+5%	+$12.4K	﹤0.01%	912
2020 Q1	$222K	Buy	264,549 +125,096	+90%	+$145K	﹤0.01%	866
2019 Q4	$134K	Sell	139,453 -11,683	-8%	-$12.8K	﹤0.01%	963
2019 Q3	$156K	Sell	151,136 -50,302	-25%	-$68.6K	﹤0.01%	863
2019 Q2	$363K	Buy	201,438 +9,511	+5%	+$15.3K	0.01%	788
2019 Q1	$361K	Buy	191,927 +62,800	+49%	+$91.9K	0.01%	821
2018 Q4	$152K	Buy	129,127 +18,773	+17%	+$33.8K	﹤0.01%	917
2018 Q3	$299K	Sell	110,354 -58,373	-35%	-$121K	﹤0.01%	867
2018 Q2	$322K	Sell	168,727 -45,100	-21%	-$91.1K	0.01%	876
2018 Q1	$449K	Sell	213,827 -4,600	-2%	-$9.86K	0.01%	793
2017 Q4	$443K	Buy	218,427 +118,900	+119%	+$247K	0.01%	777
2017 Q3	$132K	Sell	99,527 -254,364	-72%	-$316K	﹤0.01%	908
2017 Q2	$556K	Sell	353,891 -37,780	-10%	-$72.9K	0.01%	680
2017 Q1	$1.26M	Buy	391,671 +138,900	+55%	+$342K	0.03%	509
2016 Q4	$341K	Buy	+252,771	New	+$330K	0.01%	745
2016 Q3	–	Sell	-11,850	Closed	-$16K	–	1160
2016 Q2	$16K	Hold	11,850	–	–	﹤0.01%	1137
2016 Q1	$62K	Hold	11,850	–	–	﹤0.01%	1062
2015 Q4	$93K	Sell	11,850 -10,100	-46%	-$86.9K	﹤0.01%	747
2015 Q3	$185K	Sell	21,950 -34,100	-61%	-$315K	﹤0.01%	719
2015 Q2	$614K	Sell	56,050 -16,435	-23%	-$211K	0.01%	540
2015 Q1	$1.01M	Sell	72,485 -62,623	-46%	-$957K	0.02%	473
2014 Q4	$2.28M	Buy	135,108 +78,758	+140%	+$1.15M	0.04%	359
2014 Q3	$756K	Buy	+56,350	New	+$671K	0.01%	543

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jacobs Levy Equity Management's INFI Position: Q2 2022 in Review

Jacobs Levy Equity Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2022, closing a stake of 23,557 shares — an estimated $27K sold.

Jacobs Levy Equity Management first reported a position in INFI in Q3 2014 and held it in 30 quarters. The position peaked at $2.28M in Q4 2014. 77 funds tracked by Wall St. Rank hold INFI as of Q2 2022.

Jacobs Levy Equity Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 23,557 Infinity Pharmaceuticals, Inc. shares in Q2 2022, an estimated $27K.
Jacobs Levy Equity Management first reported a position in Infinity Pharmaceuticals, Inc. in Q3 2014 and held it in 30 quarters.
Jacobs Levy Equity Management's Infinity Pharmaceuticals, Inc. position peaked at $2.28M in Q4 2014.
77 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2022, filed 15 Aug 2022.